Ivabradine - NDSRI's
References
FAQ's
References
- Peglion, Jean Louis; Vian, Joel; Vilaine, Jean Paul; Villeneuve, Nicole; Janiak, Philip; Bidouard, Jean Pierre, (Benzocycloalkyl) alkylamines, ADIR et Cie., France, US5296482A, March 22, 1994
- Francois-Bouchard, M.; Simonin, G.; Bossant, M.-J.; Boursier-Neyret, C., Simultaneous determination of ivabradine and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry, Journal of Chromatography B: Biomedical Sciences and Applications, Volume: 745, Issue: 2, Pages: 261-269, 2000
Frequently Asked Questions
Can Ivabradine impurities impact the drug's bioavailability or pharmacokinetics?
Some impurities in Ivabradine can affect its bioavailability or pharmacokinetics. They may alter the drug's absorption, distribution, metabolism, or excretion, potentially influencing its therapeutic effectiveness.
Are there specific stability studies conducted to evaluate impurity formation in Ivabradine?
Yes, stability studies are conducted to assess the formation of impurities in Ivabradine over time. These studies involve subjecting the drug to various storage conditions and monitoring impurity levels to ensure product stability.
Can Ivabradine impurities be formed during storage or transportation?
Impurities in Ivabradine can potentially form during storage or transportation if the drug is exposed to unfavorable conditions such as extreme temperatures, humidity, or light. Proper storage and handling procedures are essential to minimize impurity formation.
How should Ivabradine impurities be stored in terms of temperature?
The recommendation is to store Ivabradine impurities at a controlled room temperature, within 2-8 °C.
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.